

***Remarks***

Applicants' Attorney hereby states that the change made in the sequence listing does not include new matter in accordance with 37 C.F.R. § 1.825(a). Applicants' undersigned attorney has amended the specification to direct the entry of this corrected Sequence Listing at the end of the application.

In accordance with 37 C.F.R. §§ 1.825(a) and 1.825(b), the copy in computer readable form is the same as the substitute copy of the Sequence Listing; the substitute sheets include no new matter.


The amendments herein are to correct only minor errors in the specification. In particular, the capitalization of the first letter of the word "Myc-epitope" has been corrected on page 30, line 23; and a sequence identifier has been added to reflect SEQ ID NO:4. None of the amendments add new matter.

Applicants respectfully request that this Amendment be entered.

Reconsideration of this application and entry of the above amendments are respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert  
Attorney for Applicants  
Registration No. 38,759

Date: June 17, 2008


1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

834344\_1.DOC

Reconsideration of this application and entry of the above amendments are respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
John M. Covert  
Attorney for Applicants  
Registration No. 38,759

Date: June 17, 2008

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

834344\_1.DOC